WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319545
Description: Eleclazine, also known as GS-6615, is a selective late sodium current inhibitor. Eleclazine is potentially useful for treatment of coronary vasodilators, antiarrhythmics and vasodilators. Eleclazin showed a shortening of the QTc interval (the time interval between the start of the Q-wave and end of the T-wave in the heart’s electrical cycle) in patients with long QT-3 (LQT3) syndrome. LQT3 is a genetic disorder that prolongs the heart’s QTc interval and can cause life-threatening cardiac arrhythmias (abnormal heartbeats).
MedKoo Cat#: 319545
Chemical Formula: C21H16F3N3O3
Exact Mass: 415.1144
Molecular Weight: 415.37
Elemental Analysis: C, 60.72; H, 3.88; F, 13.72; N, 10.12; O, 11.56
Eleclazine is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: GS-6615; GS 6615; GS6615; Eleclazine.
IUPAC/Chemical Name: 4-[(pyrimidin-2-yl)methyl]-7-[4-(trifluoromethoxy)phenyl]- 3,4-dihydro-1,4-benzoxazepin-5(2H)-one
InChi Key: YNUAEEJQYHYLMS-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2
SMILES Code: O=C1N(CC2=NC=CC=N2)CCOC3=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=C13
The following data is based on the product molecular weight 415.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Fuller H, Justo F, Nearing BD, Kahlig KM, Rajamani S, Belardinelli L, Verrier
RL. Eleclazine, a new selective cardiac late sodium current inhibitor, confers
concurrent protection against autonomically induced atrial premature beats,
repolarization alternans and heterogeneity, and atrial fibrillation in an intact
porcine model. Heart Rhythm. 2016 Apr 21. pii: S1547-5271(16)30211-9. doi:
10.1016/j.hrthm.2016.04.015. [Epub ahead of print] PubMed PMID: 27108587.